14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for CYTK

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 67.23 3.00 %
R2 66.62 2.06 %
R1 66.24 1.48 %
Current price: 65.27
Support S1 65.01 -0.395 %
S2 64.63 -0.98 %
S3 64.02 -1.92 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 73.09 11.98 %
R2 71.15 9.01 %
R1 67.68 3.69 %
Current price 65.27
Support S1 65.19 -0.123%
S2 64.39 -1.35%
S3 63.75 -2.33%

CYTK Predictions History

4 years ago
JS predicted that CYTK for 2020-02-07 is going $13.89 (-4.73%)

4 years ago
Options and Traders predicted that CYTK for 2020-02-07 is going $14.50 (-0.55%)

Rank:

4 years ago
2poJeff predicted that CYTK for 2020-02-07 is going $14.52 (2.98%)

4 years ago
Grayigami predicted that CYTK for 2020-02-07 is going $14.13 (0.18%)

Rank:

4 years ago
GoldenNugget predicted that CYTK for 2019-05-07 is going $8.89 (-6.24%)

5 years ago
NameNotImportant predicted that CYTK for 2019-05-02 is going $9.11 (7.81%)

5 years ago
NameNotImportant predicted that CYTK for 2019-05-01 is going $8.50 (2.16%)

5 years ago
NameNotImportant predicted that CYTK for 2019-04-23 is going $8.08 (-9.82%)

6 years ago
JS predicted that CYTK for 2018-01-11 is going $9.23 (4.89%)

7 years ago
JS predicted that CYTK for 2017-03-07 is going $11.97 (4.09%)

Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT